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Summary
Effects of two weeks treatment with niacin-oxyethylidendip-
hosphonato-germanate (MIGU-4, 2,5; 25,0 mg/kg, i.p.) and 
alpha-lipoic acid (LA, 5,0 and 50,0 mg/kg, i.p.) as well as 
their combined usage (MIGU-4 – 2,5, and LA – 5,0 mg/kg) 
upon antioxidative enzymes and level of malon dialdehyde 
(MDA) in retina tissue of rats with streptozotocin (STZ)-
induced diabetes was determined. It was established that in 
six weeks after STZ administration superoxiddismutase (SOD) 
activity decreased by 33,4% (P<0,05), catalase (CAT) – by 
28,2% (P<0,05), glutathione peroxidase (GPx) – by 39,8%, 
glutathione reductase (GR) – by 48,3%, and MDA level raised 
by 2,65 times when compared with intact rats (P<0,05). 
MIGU-4 treatment (25,0 mg/kg, i.p.) increased SOD activity 
by 38,1% (P<0,05), GPx and GR – by 62,9% (P<0,05) and 
by 35,2% (P<0,05), when compared with diabetes rats. MDA 
level was reduced by 30,2% (P<0,05) correspondently. The 
SOD activity under condition of combined MIGU-4 (2,5 mg/
kg) and LA (5,0 mg/kg) administration exceeded its level in 
rats with diabetes by 41,3% (P<0,05), while activity of GPx 
and GR also was higher by 52,4% and by 47,8% (P<0,05) 
correspondently. MDA level reduction was higher than in 
groups which were given MIGU-4 or LA alone (P<0,05). Thus, 
niacin-oxyethylidendiphosphonato-germanate caused preven-
tion on diabetes-induced deterioration of antioxidant enzymes 
activity and level of MDA in retina tissue. Combined usage of 
MIGU-4 and LA was resulted in heightened preventive effects 
upon manifestations of oxidative stress.
Keywords: experimental diabetes mellitus, streptozotocin, 
diabetes retinopathy, niacin-oxyethylidendiphosphonato-
germanate, lipoic acid, oxidative stress
Rezumat
Efectele acidului nicacin-oxetilendendifosfonat germanat 
și acidului alfa-lipoic asupra stresului oxidativ indus de 
diabet în ţesutul retinei 
Au fost investigate efectele administrării de două săptămâni 
a hidroxietilidendifosfonat germanatului (MIGU-4, 2,5; 25,0 
mg/kg, i.p.) și a acidului alfa-lipoic (LC, 5,0 și 50,0 mg/kg, i.p.) 
și efectul utilizării lor combinate (MIGU-4 – 2,5 și LC – 5,0 
mg/kg) asupra activităţii enzimelor antioxidante și nivelului 
de malondialdehidă (MDA) în ţesutul retinei șobolanilor cu 
diabet indus de streptozotocină (STZ). S-a constatat că după 6 
săptămâni de la momentul aplicării STZ, activitatea superoxid 
dismutazei (SOD) a scăzut cu 33,4% (P <0,05), a catalazei 
(CAT) – cu 28,2% (P <0,05), a glutationperoxidazei – cu 
39,8%, a glutationreductazei (GR) – cu 48,3%, cu o creștere 
a conţinutului de MDA de 2,65 ori, comparativ cu șobolanii 
intacţi (P <0,05). Odată cu introducerea MIGU-4 (25,0 mg/kg, 
i.p.), activitatea SOD a fost mai mare cu 38,1% (P <0,05), a
HP și GR – cu 62,9% (P <0,05 ) și, respectiv, 35,2% (P <0,05), 
în comparaţie cu animalele cu diabet zaharat. Nivelul MDA 
a scăzut cu 30,2% (P <0,05). Eficacitatea MIGU-4 (25,0 mg/
kg) a fost comparabilă cu cea a LK utilizată în doză de 50,0 
mg/kg. În cazul folosirii combinate a MIGU-4 (2,5 mg/kg) și 
a LC (5,0 mg/kg), activitatea SOD a depășit-o pe cea a șobo-
lanilor cu diabet zaharat cu 41,3% (P <0,05), GP și GR fiind 
mai mari cu 52,4% și, respectiv, cu 47,8% (P <0,05). Scăderea 
nivelului MDA a fost mai mare decât în cazul grupurilor care 
utilizează MIGU-4 sau LC (P <0,05). Astfel, administrarea 
hidroxietildidenfosfonat germanatului previne dereglările 
activităţii enzimelor antioxidante și nivelului MDA induse de 
diabet în ţesutul retinian. Administrarea asociată a MIGU-4 
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și a LC este însoţită de o acţiune preventivă sporită împotriva 
manifestărilor stresului oxidativ. 
Cuvinte-cheie: diabet experimental, streptozotocin, retino-
patie diabetică, niacin-oxietildendifosfonat germanat, acid 
lipoic, stres oxidativ
Резюме
Эффекты ниацин-оксиэтилидендифософнат 
германата и альфа-липоевой кислоты на диабет-
индуцированный оксидантный стресс в ткани сет-
чатки
Исследовали влияние двухнедельного введения ниацин-
оксиэтилидендифосфонат германата (МИГУ-4, 2,5; 
25,0 мг/кг, в/бр) и альфа-липоевой кислоты (ЛК, 5,0 и 
50,0 мг/кг, в/бр), а также влияние их совместного при-
менения (МИГУ-4 – 2,5, и ЛК – 5,0 мг/кг) на активность 
антиоксидантних ферментов и уровень малонового 
диальдегида (МДА) в ткани сетчатки крыс со стреп-
тозотоцин (СТЗ)-индуцированным диабетом. Уста-
новлено, что через 6 недель с момента применения СТЗ 
активность супероксидисмутазы (СОД) уменьшилась 
на 33,4% (P<0,05), каталазы (КАТ) – на 28,2% (P<0,05), 
глутатионпероксидазы (ГП) – на 39,8%, глутатион-
редуктазы (ГР) – на 48,3% при увеличении содержания 
МДА в 2,65 раза в сравнении с интактными крысами 
(P<0,05). На фоне введения МИГУ-4 (25,0 мг/кг, в/бр) 
активность СОД была выше на 38,1% (P<0,05), ГП и 
ГР – на 62,9% (P<0,05) и соответственно 35,2% (P<0,05) 
при сравнении с животными с диабетом. При этом 
уровень МДА уменьшался на 30,2% (P<0,05). При ком-
бинированном применении МИГУ-4 (2,5 мг/кг) и ЛК (5,0 
мг/кг) активность СОД превышала таковую у крыс с 
диабетом на 41,3% (P<0,05), в то время как активность 
ГП и ГР была выше на 52,4% и соответственно 47,8% 
(P<0,05) соответственно. Величина снижения уровня 
МДА была выше, чем в группах с применением одного 
МИГУ-4 или ЛК (P<0,05). Таким образом, применение 
ниацин-оксиэтилидендифосфонат германата предот-
вращает диабет-вызванные нарушения активности 
антиоксидантных ферментов и уровня МДА в ткани 
сетчатки. Совместное введение МИГУ-4 и ЛК сопрово-
ждается потенцированным превентивным действием в 
отношении проявлений оксидативного стресса.
Ключевые слова: экспериментальный диабет, стреп-
тозотоцин, диабетическая ретинопатия, ниацин-
оксиэтилидендифосфонат германат, липоевая кислота, 
оксидативный стресс
Introduction
The intensification of mechanisms of oxidative 
stress in retinal tissue is regarded as a key mechanism 
of diabetes retinopathy development [1, 2]. Those 
drugs, which alleviate diabetes retinopathy mani-
festations are known as such ones which suppress 
oxidative stress as well [3].
during last years the pharmacological activity 
of different derivatives of germanium has been 
investigated at our laboratory [4, 5]. Among others 
such one as oxyethylidendiphosphonate germanate: 
(nich)2 [ge(oh)2 (oedph)].h20 (migu-4) with molecu-
lar weight of 593 g/m was identified as perspective 
compound. it was established that migu-4 intensify 
oxidative phosphorilation, prevented discordant state 
of mitochondrial ATP-ases and heightened mitochon-
drial resistance to damages. such pharmacological 
properties of migu-4 led to the stabilization of mito-
chondrial membrane phospholipids, and suppressed 
an oxidative stress – both on behalf of enzymatic and 
antiradical components of defense [5, 6].
That is why it was reasonable to investigate 
effects of migu-4 upon diabetes-induced experi-
mental retinopathy. hence, the aim of work was to 
investigate activity of antioxidative enzymes in retina 
of rats with experimental diabetes under condition 
of treatment with migu-4, and to compare effects 
with such ones caused by alpha-lipoic acid (lA), 
which is used for diabetes retinopathy treatment. 
Material and methods
investigations were performed on 94 Wistar 
male rats with body weight of 170- 240 g, which 
were kept under standard conditions at odessa 
national medical university (onmedu) vivarium. 
Animals were randomly allocated to the following 
conditions: a constant temperature of 23oc, relative 
humidity of 60%, 12 h dark/light cycles, a standard 
diet, and tap water were given ad libitum in accor-
dance to international laws and policies (Eu council 
directive 86/609, oJ l 358, 18/12/1986 P.0001-0028; 
national institute of health guide for care and use of 
laboratory Animals, us national Research council, 
1996, p. 21-55) and in strict accordance to prescrip-
tions issued by commission on Bioethic at onmedu 
(Protocol no 84, 10th october, 2008).
Experimental diabetes was induced via i.p. 
streptozotocin (sTZ, Sigma Aldrich.ru RF) adminis-
tration (55,0 mg/kg) which was dissolved in sodium-
citrate buffer solution (рн 4,5). The level of glucose 
was determined in vein blood in one week from the 
moment of sTZ administration and those rats with le-
vel not less than 300 mg/dl have been included into 
observation [1, 3]. measurements were performed 
at 9.00 Am under conditions of free access to water 
and food during night time. insulin administration 
(0,2 iu, subcutaneously, two-five times per week) was 
performed during all period of observation [1, 3]. 
The treatment with migu-4 and lA was per-
formed during fifth-sixth weeks from the moment 
of diabetes modeling via sTZ administration. Both 
drugs were administered daily and tissues for mea-
surement of enzyme activity and mdA level were got 
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in 24 h from the moment of last (14th) administration. 
After euthanasia was performed retina was got and 
kept in liquid nitrogen.
Retina tissue washed out from blood remnants 
with a buffer solution was homogenized in 0,1m 
phosphate buffer solution (рн 7,0) at the ratio of 1:20 
(weight of tissue/volume of homogenate). homoge-
nized samples were centrifugated during 15 min at 
velocity of 13.000 rotations/min at + 4ос.
sod activity was determined in accordance to 
[7], cAT – [8], gPx – [9], and gR – [10] methods.
mdA was determined with spectrophotometric 
method [11]. The incubation of homogenate was 
performed at high temperature with thiobarbituric 
acid and gained pink solution was investigated at 
532 nm length of wave. The tetraoxypropane so-
lution was used as a standard. The mdA level was 
expressed as nmoles/mg of proptein. The protein 
level was determined in accordance to lowery me-
thod [11]. 
Results of investigation were statistically 
analyzed using AnoVA method and followed with 
newman-Keuls test.
results and discussion
Effects of MiGU-4 administrations. obtained 
data revealed that in rats with diabetes the signifi-
cant reduction of investigated enzymes activity was 
detected (table 1). Thus, superoxide dismutase (sod, 
Ec 1.15.1.1) was reduced by 33,4% (P<0,05), cAT (Ec 
1.11.1.6) – by 28,2% (P<0,05), glutathione peroxidase 
(gPx, Ec 1.11.1.9) and glutathione reductase (gR, Ec 
1.8.1.7) – by 39,8% and by 48,3% (P<0,05) pertained 
to corresponded data registered in control rats. Be-
sides, the increased level of mdA, which exceeded 
such one in the control group by 2,65 times was also 
observed (P<0,05).
in the group of rats treated with migu-4 in 
lower dosage (2,5 mg/kg, i.p.) sod activity increased 
by 7,6% when compared with such one in the rats 
with diabetes (P>0,05), and cAT activity also have 
been raised by 5,2% (P>0,05). meanwhile the gPx 
activity exceeded initial value by 15,8% (P>0,05), 
while gR activity also raised by 17,6% (P>0,05). mdA 
level was higher when compared with the initial one 
by 6,8% (P>0,05). 
migu-4 (25,0 mg/kg, i.p.) administration was 
followed by sod activity increasing by 38,1% when 
compared with diabetes rats (P<0,05) and was not 
differ from such one registered in the control group 
(P>0,05). The cAT activity also increased by 32,0% 
(P<0,05), while gPx and gR activity exceeded initial 
values by 62,9% (P<0,05) and by 35,2% (P<0,05) 
correspondently. cAT and gPx activity was not differ 
from control values, and gR activity remained redu-
ced by 30,1% (P<0,05). The mdA level was less when 
compared with diabetes rats by 30,2% (P<0,05) and 
continued to be reduced when compared with the 
control group – by 85,0% (P<0,05) (table 1).
Table 1
The activity of antioxidative enzymes in retinal tissue (6 
weeks from the moment of STZ-administration) under con-
ditions of MIGU-4 treatment (M+m)
Control 
group 
(intact rats, 
vehicle i.p.) 
(n=11)
SТZ-
diabetes
(n=11)
STZ-
diabetes + 
МIGU-4 (2,5 
mg/kg)
(n=10)
STZ-
diabetes 
+ МІGU-4 
(25,0 mg/
kg)
(n=10)
superoxide 
dismuta-
se (% of 
blocking of 
nitroblue 
tetrazolium 
reduction)
121,3+5,56 80,80+ 6,53* 86,97+6,59* 111,6+ 7,71#
cAT (н2о2/ 
(min.mg of 
protein)
3,48+0,23 2,50+0,18* 2,63+0,24* 3,30+ 0,27#
glutathione 
peroxidase 
(gsh/(min.
mg of pro-
tein), nм)
1,03+0,07 0,62+0,05* 0,78+0,08 1,01+ 0,09#
glutathione 
reductase 
(nAdPh/
(min.mg of 
protein), 
nм)
12,84+0,61 6,64+0,56* 7,81+0,55* 8,98+0,44*#
malon 
dialdehyde 
(nm/mg of 
protein)
2,00+0,18 5,30+0,43* 4,94+0,41* 3,70+ 0,25*#
Notes. * – P<0,05 when compared with the data in the 
control group (intact false operated rats); # – P<0,05 when 
compared with the data in diabetes rats. method AnoVA 
+ newman-Keuls test were used. 
alpha-lipoic acid (la) effects. lA administrati-
on in a lower dosage (5,0 mg/kg, i.p.) was followed by 
the tendency of the antioxidant enzymes increasing 
with the gR activity heightened by 35,0% as a grea-
test one (P<0,05) (table 2). At the same time the sod 
activity raised by 22,7% (P>0,05), while cAT activity 
increased only by 2,8% (P>0,05). meanwhile, both 
sod and cAT activity continued to be less when 
compared with control data – by 32,7% (P<0,05) and 
by 23,8% (P<0,05) correspondently. The mdA level 
decreased by 9,9% when compared with diabetes 
rats (P>0,05). 
lA administered in a dosage of 50,0 mg/kg, i.p. 
caused more pronounced effect when all investiga-
ted indices – activities of enzymes were did not differ 
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from the corresponded data in the control group 
(P>0,05). Besides, sod and gR activity exceeded the 
value of analogous indices in the control group by 
37,2% and by 43,9% (P<0,05) correspondently. The 
mdA level also was reduced when compared with 
the control group by 42,1% (P<0,05) and continued 
to be greater than such one in rats with diabetes by 
1,65 times (P<0,05) (table 2).
Table 2
Antioxidative enzymes activity in rat retina (six weeks from 
the moment of diabetes modeling via STZ administration) 
under conditions of alpha-lipoic acid treatment (M+m)
Control 
group 
(intact rats, 
vehicle i.p.) 
(n=11)
STZ- 
diabetes
(n=11)
STZ-diabe-
tes + LA  
(5,0 mg/kg)
(n=10)
STZ-dia-
betes + LA 
(50,0 mg/
kg)
(n=10)
superoxide 
dismutase 
(% of 
blocking of 
nitroblue 
tetrazolium 
reduction)
111,39+7,44 61,06+6,69* 74,93+6,94* 97,22+7,77#
cAT (н2о2/ 
(min.mg of 
protein)
3,32+0,21 2,46+0,19* 2,53+0,24* 3,10+0,26
glutathione 
peroxidase 
(gsh/ (min.
mg of pro-
tein), nм)
1,04+ 0,07 0,69+0,07* 0,75+0,08 0,98+0,12
glutathione 
reductase 
(nAdPh/ 
(min.mg of 
protein), 
nм)
13,21+0,99 8,74+0,81* 11,80+1,10# 12,58+1,21#
malon 
dialdehyde 
(nm/mg of 
protein)
1,96+0,14 5,58+0,52* 5,03+0,46* 3,23+0,25#*
Notes. The same as in table 1.
Effects of combined usage of MiGU-4 and la. 
combined administration of migu-4 and lA in lower 
dosages (2,5 mg/kg and 5,0 mg/kg correspondently) 
resulted in sod activity increasing by 41,3% per-
tained to the level observed in rats with diabetes 
(P<0,05) (table 3). Besides, the activity of gPx and gR 
have been increased also when compared with the 
data in rats with diabetes – by 52,4% and by 47,8% 
correspondently (P<0,05). it should be stressed that 
in this session of experimental observation lA admi-
nistration (5,0 mg/ kg, i.p.) effectively prevented gPx 
activity decreasing, which significantly exceeded the 
corresponded value in rats with diabetes – by 52,4% 
(P<0,05). There were any significant differences be-
tween enzymatic activity in groups with separate 
and combined usage of migu-4 and lA (P>0,05). 
Table 3
Antioxidant enzymes activity in retina tissue (6 weeks from 
the moment of STZ – administration) under conditions of 
treatment with MIGU-4 and alpha-lipoic acid (M+m)
Control 
(intact rats, 
vehicle i.p.) 
(n=11)
STZ-diabetes 
(n=10)
MIGU – 4 
(2,5 mg/kg)
(n=11)
LA  
(5,0 mg/kg) 
(n=10)
MIGU-4 + LA 
(n=10)
superoxide 
dismutase 
(% of 
blocking of 
nitroblue 
tetrazolium 
reduction)
120,5+6,4 74,3+5,9* 86,97+ 6,59* 78,12+ 7,88* 105,03+ 9,62#
cAT (н2о2/ 
(min.mg of 
protein)
3,28+0,20 2,33+0,22* 2,63+0,24 2,87+0,25 3,08+ 0,26
glutathione 
peroxidase 
(gsh/ 
(min.mg of 
protein), 
nм)
1,07+0,07 0,63+0,05* 0,75+0,06* 0,89+0,07# 0,96+0,08#
glutathione 
reductase 
(nAdPh/
(min.mg of 
protein), 
nм)
14,49+0,80 9,37+0,64* 11,06+1,16* 12,13+0,86 13,85+0,93#
malon 
dialdehyde 
(nm/mg of 
protein)
1,96+0,14 5,54+0,60* 5,30+0,43* 4,95+ 0,27* 3,09+0,21#*
Notes. The same as in table 1.
mdA level was reduced by 44,2% (P<0,05) per-
tained to rats with diabetes and exceeded the cor-
responded level in control group by 57,6% (P<0,05). 
it should be stressed that mdA level in rats given 
combined treatment was significantly less when 
compared with such one in the groups treated with 
migu-4 – by 41,7%, (P<0,05) and lA – by 37,6%, 
(P<0,05) (table 3). 
hence, gained data are in favor that in six 
weeks from the moment of experimental diabetes 
modeling via sTZ administration the net reduction 
of antioxidant enzymes activity is registered in rat’s 
retina. namely, sod activity decreased by 33,4% 
(P<0,05), cAT – by 28,2% (P<0,05), gPx – by 39,8% 
and gR – by 48,3% when compared with correspon-
ded data in the control group (P<0,05). Besides, mdA 
level raised by 2,65 times pertained to control data 
(P<0,05). such data are in correspondence with other 
investigations [1].
migu-4 (25,0 mg/kg, i.p.) administration per-
formed during fifth-sixth weeks from the moment 
of sTZ administration prevented the mentioned 
reduction of antioxidant enzymes activity reduction 
and raising of mdA level. Thus, sod activity increased 
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by 38,1% (P<0,05), gPx and gR – by 62,9% (P<0,05) 
and by 35,2% (P<0,05), when compared with cor-
responded data in rats with diabetes. At the same 
time mdA level was reduced by 30,2% (P<0,05) 
when compared with diabetes rats. The pronounced 
tendency to gPx activity raising was also noted in 
diabetes rats treated with migu-4 in lower dosage 
(2,5 mg/kg, i.p.). such effectiveness was also obser-
ved for ge- containing compounds in case of other 
types of oxidative stress [12, 13].
obtained data were in favor for the effective-
ness of lA treatment against sTZ-diabetes-induced 
oxidative stress in retina tissue. Thus, even lower 
dosage of lA (5,0 mg/kg, i.p.) prevented diabetes-
induced decreasing of gR activity, which exceeded 
such one in rats with diabetes by 35,0% (P<0,05), 
and in higher dosage (50,0 mg/ kg, i.p.) such diffe-
rence raised up to 43,9% (P<0,05). Besides, higher 
dosage of lA effectively prevented sod activity 
decreasing, and it’s activity exceeded control value 
by 37,2% (P<0,05). At the same time the mdA level 
decreased by 42,1% pertained to level in diabetes 
rats (P<0,05). 
The comparison of the pronouncement of pro-
tective effects of migu-4 revealed that in dosage of 
25,0 mg/kg they are equal to such one caused by 
lA administered in a dosage of 50,0 mg/kg. But in 
lower dosages lA administration (5,0 mg/kg) was 
followed by more pronounced effects than migu-4 
(2,5 mg/kg). such differences might be explained by 
realization of lA protective action via influence upon 
glutamate turnover, which plays an important role 
in diabetes retinopathy [1, 2].
combined administration of migu-4 (2,5 mg/
kg) and lA (5,0 mg/kg) caused the prevention of di-
abetes-induced sod activity decreasing: it exceeded 
by 41,3% similar index in rats with diabetes (P<0,05). 
The activity of gPx and gR also exceeded such ones 
in rats with diabetes – by 52,4% and by 47,8% cor-
respondently (P<0,05). The absence of differences 
between enzymatic activity in groups with separate 
and combined usage of migu-4 and lA was in favor 
for the summation as a main mechanism of their 
combined therapeutic preventive action. 
it should be stressed that mdA level in rats 
given combined treatment was significantly less 
when compared with such one in the groups treated 
with migu-4 – by 41,7%, (P<0,05) and lA – by 37,6%, 
(P<0,05). This fact is in favor for potentiating as the 
main mechanism of migu-4 and lA interaction with 
respect to prevention of mdA level increasing in 
sTZ-induced diabetes. But, absence of mentioned 
differences in the case of effects upon enzymatic 
activity assumes summation of preventive activity 
of migu-4 and lA as well.
Conclusions
1. Retinopathy in sTZ-induced diabetes is cha-
racterized by reduction of antioxidants enzymes – 
superoxiddismutase, catalase, glutathione peroxida-
se, glutathione redusctase activity and accumulation 
of malon dialdehyde in retina tissue.
2. niacin-oxyethylidendiphosphonato-ger-
manate (25,0 mg/kg, i.p.) caused preventive effects 
upon diabetes-induced oxidative stress in retina 
tissue, and pronouncement of activity is comparable 
with such one induced with alpha-lipoic acid used 
in a dosage of 50,0 mg/kg, i.p.
3. combined usage of niacin-oxyethyliden-
diphosphonato-germanate and alpha-lipoic acid 
are followed with strengthened protective effects 
which might be regarded as effect of summation in 
case of correction of antioxidant enzymes activity 
and as potentiating in case of correction of mdA 
accumulation.
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